These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Genetic manipulation of hematopoietic stem cells in adenosine deaminase deficiency. Williams DA; Moritz T Adv Exp Med Biol; 1994; 370():395-400. PubMed ID: 7660937 [No Abstract] [Full Text] [Related]
29. Gene therapy. Patent award stirs a controversy. Nowak R Science; 1995 Mar; 267(5206):1899. PubMed ID: 7701313 [No Abstract] [Full Text] [Related]
30. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID. Schimmer J; Breazzano S Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267 [TBL] [Abstract][Full Text] [Related]
31. Retroviral transfer of human MDR1 gene into human T lymphocytes. Lee CG; Pastan I; Gottesman MM Methods Enzymol; 1998; 292():557-72. PubMed ID: 9711583 [No Abstract] [Full Text] [Related]
32. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies. Silver JN; Flotte TR Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656 [TBL] [Abstract][Full Text] [Related]
33. Evolving Gene Therapy in Primary Immunodeficiency. Thrasher AJ; Williams DA Mol Ther; 2017 May; 25(5):1132-1141. PubMed ID: 28366768 [TBL] [Abstract][Full Text] [Related]
34. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507 [TBL] [Abstract][Full Text] [Related]
35. EMA greenlights second gene therapy. Mullard A Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988 [No Abstract] [Full Text] [Related]
36. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494 [TBL] [Abstract][Full Text] [Related]
37. R. Michael Blaese: still blazing a path of his own. Jenks S J Natl Cancer Inst; 1998 Aug; 90(16):1188-91. PubMed ID: 9719076 [No Abstract] [Full Text] [Related]
38. Bone marrow gene therapy for adenosine deaminase deficiency. Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479 [TBL] [Abstract][Full Text] [Related]
39. Bone marrow stromal cell-mediated gene therapy for hemophilia A: in vitro expression of human factor VIII with high biological activity requires the inclusion of the proteolytic site at amino acid 1648. Chiang GG; Rubin HL; Cherington V; Wang T; Sobolewski J; McGrath CA; Gaffney A; Emami S; Sarver N; Levine PH; Greenberger JS; Hurwitz DR Hum Gene Ther; 1999 Jan; 10(1):61-76. PubMed ID: 10022531 [TBL] [Abstract][Full Text] [Related]